CRS Clinical Research Services Andernach GmbH. (4/19/19). "Press Release: CRS Receives CRO Leadership Awards. Recognised for Excellence in Early Clinical Development". Andernach.

	Organisation	CRS Clinical Research Services Andernach GmbH
	Group	CRS Clinical Research Services (Group)
	Product	contract research (drugs)
	Product 2	phase 1 study
	Person	Thomsen, Torben (CRS 201307 Managing Director + Shareholder)
	Person 2	Zepp, Tobias (CRS Clinical Research Services 201706 Corporate Communications Manager)

CRS is proud to announce that it has again won a CRO Leadership Award in 2019. CRS was honored for its outstanding performance in the areas of capabilities, compatibility, quality and reliability.

CRS, a leading European full-service clinical research organization (CRO) with a focus on Phase I and Phase II clinical research, has been recognised with awards across four categories in the annual CRO Leadership Awards from Life Science Leader magazine.

Winning categories for CRS:

> Capabilities | Overall (combined Big and Small Pharma)
> Compatibility | Overall (combined Big and Small Pharma)
> Quality | Overall (combined Big and Small Pharma)
> Reliability | Overall (combined Big and Small Pharma)

The CRO Leadership Awards provide accurate and reliable customer feedback and help select a trusted partner for clinical research. To determine the award recipients, Life Science Leader Magazine once again joined forces with Industry Standard Research (ISR) in 2019. 60 contract research organisations were evaluated in the ISR's annual CRO Quality Benchmarking survey using more than 20 key performance indicators.

CRS previously received CRO Leadership Awards in 2018 and 2016.

“It is a great privilege that our efforts to achieve highest client satisfaction are recognised again by these awards. This appreciation is based on our expertise and know-how built up over more than 40 years in clinical research. To be leading in four core categories confirms our continuous strive for excellence. The outstanding quality and reliability of CRS is reflected by the high number of satisfied clients who repeatedly entrust us with the conduct of Early Phase clinical trials,” commented Dr Torben Thomsen, Chief Executive Officer of CRS.

“Life Science Leader is proud to once again be working with ISR Reports to honor those CROs that have proven themselves to be the top performers in Compatibility, Capabilities, Expertise, Quality, Reliability, and Phase IV,” commented Ed Miseta, Executive Editor of Life Science Leader. “The winners are selected by their pharma clients, who rate their CROs on 20+ different performance metrics. We believe the CROs receiving an award this year are truly at the top of their class and are deserving of this recognition. Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of biopharmaceutical companies and their patients.”

“Industry Standard Research continues to consider it an honor to provide the primary market research data for Life Science Leader’s CRO Leadership Awards. ISR’s stringent screening processes ensures that only highly qualified industry decision makers participate in our CRO benchmarking market research,” commented Andrew Schafer, President of Industry Standard Research. “This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enables users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.”

CRS. Experts. Early Phase.

CRS is a leading European full-service CRO with a total of 300 employees. CRS conducts clinical trials for pharmaceuticals and medical devices at its clinical pharmacology units (CPUs) across Germany. CRS's excellent track record is based on over four decades of experience in clinical research, and the very highest standards of quality and safety, with which it helps develop the medicine of tomorrow. Its focus is on Phase I (first-time testing on healthy test subjects for compatibility and safety) and Phase II (therapy concept testing and therapy dose-ranging) clinical trials.

CRS was founded in 2006 following the merger of three clinical research organisations and, in 2013, took over the CPUs of Bayer HealthCare AG within the framework of a strategic partnership. In 2017, Apleonex AG acquired the shares of the main shareholder LTS AG as part of a management buy-out. Dr Torben Thomsen, CEO and partner of CRS for many years, is the sole managing director of Apleonex.

Further information is available at www.crs-group.de

Media Contact
Tobias Zepp, MA
Corporate Communications Manager
CRS Clinical Research Services Andernach GmbH
Rennweg 72
56626 Andernach
+49 (0) 2632 – 958 04 06

Record changed: 2023-06-05